Bruker reported FY 2025 revenue of USD 3.4 billion (+2.1%), with product revenue of USD 2.8 billion (+0.3%) and service and other revenue of USD 670.1 million (+10.4%). FY 2025 gross profit was USD 1.6 billion with a 45.9% gross margin, while operating income was USD 68.2 million (2.0% operating margin). Bruker posted a FY 2025 net loss attributable to common shareholders of USD 22.5 million, and net cash provided by operating activities was USD 134.1 million; free cash flow was USD 43.3 million. By segment in FY 2025, revenue was USD 1.2 billion (+10.7%) for BSI CALID, USD 1.1 billion (-1.3%) for BSI NANO, USD 878.8 million (-3.0%) for BSI BioSpin, and USD 270.9 million (-4.3%) for BEST. Bruker said the revenue increase was driven mostly by ELITechGroup within BSI CALID and NanoString within BSI NANO, partially offset by organic revenue decline; BioSpin was impacted by fewer GHz-class NMR system sales (two in 2025 versus four in 2024). Bruker recorded a FY 2025 goodwill impairment charge of USD 96.5 million related to the Bruker Spatial Biology reporting unit (BSI NANO) and the Automation reporting unit (BSI BioSpin). The company also cited higher U.S. tariffs and foreign exchange headwinds from a declining U.S. Dollar as factors that reduced gross and operating margins. Bruker announced in August 2025 a cost savings initiative targeting approximately USD 100 million to USD 120 million in annualized cost reductions by the end of 2026. In financing and capital structure updates, Bruker issued USD 690 million of 6.375% Series A Mandatory Convertible Preferred Stock in September 2025, and used the proceeds to repay USD 255.8 million of its 2019 term loan, repay USD 300 million under its 2024 revolving credit agreement, and repay USD 37.6 million of its 2024 term loan due 2027. Total outstanding debt was USD 1.9 billion as of December 31, 2025, with USD 899.3 million available under its revolving credit facility.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-082523), on February 27, 2026, and is solely responsible for the information contained therein.
Comments